Holding Instructions for Eliquis (Apixaban) Before Cervical Neck Ablation
For cervical neck ablation, which carries high bleeding risk, hold apixaban for 2 days (48 hours) before the procedure, with the last dose taken 2 days prior to surgery. 1
Pre-Procedure Management
Timing of Interruption
The FDA label for Eliquis provides the most direct guidance: discontinue apixaban at least 48 hours prior to elective surgery or invasive procedures with moderate or high risk of bleeding 1. Cervical neck ablation falls into this high-risk category due to:
- Proximity to critical vascular structures
- Limited ability to achieve local hemostasis
- Potential for airway compromise from hematoma formation
This recommendation is consistently supported across multiple guidelines:
- 2025 Australian/New Zealand guidelines: Omit apixaban for 2 days before and the day of surgery for high bleeding risk procedures 2
- 2018 European Heart Rhythm Association: Stop apixaban ≥48 hours before high-risk procedures 3
- 2014 Canadian Cardiovascular Society: Interrupt apixaban 2-3 days before procedures with intermediate or high bleeding risk 4
Practical Implementation
Last dose timing: If the procedure is scheduled for morning, take the last dose of apixaban 2 evenings before surgery (skip 4 doses total for twice-daily dosing).
No bridging required: The FDA label explicitly states that "bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required" 1. This is because apixaban has a short half-life (approximately 12 hours) and rapid offset of action 3, 2.
Special Considerations
Renal function matters: If creatinine clearance is <30 mL/min, consider extending the interruption period. The 2018 EHRA guidelines suggest holding for ≥48 hours even with renal impairment for high-risk procedures 3, while the 2025 guidelines recommend extending to 3 days (omit for 2 days plus day of surgery) if CrCl <50 mL/min 2.
Dose-specific guidance: For patients on the reduced dose of apixaban 2.5 mg twice daily, the same 48-hour interruption applies for high bleeding risk procedures 2.
Post-Procedure Resumption
Resume apixaban 48-72 hours after the procedure once adequate hemostasis is established 4, 1. The FDA label states to restart "as soon as adequate hemostasis has been established" 1.
More specifically:
- High bleeding risk procedures: Resume 2-3 days (48-72 hours) postoperatively 5
- Consider reduced initial dosing: For patients at high thromboembolism risk, some experts suggest starting with apixaban 2.5 mg twice daily for the first 2-3 days, then increasing to full dose 5
Post-Procedure Algorithm
- Day 0 (procedure day): No apixaban
- Day +1: Assess for bleeding complications; if minimal bleeding, consider prophylactic dosing
- Day +2-3: If hemostasis secure, resume full-dose apixaban (typically 48-72 hours post-procedure)
- High thrombotic risk patients (CHADS₂ ≥3, recent stroke/TIA): Consider reduced-dose apixaban starting day +1, then full dose day +3
Critical Pitfalls to Avoid
Do not measure routine coagulation tests: Standard INR or aPTT are insensitive for apixaban levels and should not guide timing 6. Drug-specific anti-Xa levels are only needed in patients with severe renal impairment or urgent surgery 2.
Do not use heparin bridging: This increases bleeding risk without reducing thromboembolism and is explicitly not recommended 2, 7, 6, 1.
Do not resume too early: The most common error is restarting anticoagulation before adequate surgical hemostasis, particularly in high bleeding risk procedures like cervical ablation where even small hematomas can cause airway compromise 4.
Verify patient compliance: Ensure the patient understands to hold both the morning and evening doses for the 2 days prior to surgery—this means skipping 4 total doses for twice-daily apixaban 3.